Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH -- Ignore unavailable to you. Want to Upgrade?

To: RealMuLan who wrote (632)	4/7/1998 3:20:00 AM
From: GW	Read Replies (2) \| Respond to of 998

Wow, the remark from analyst looks like more trouble ahead for longer term...BAD NEWs for CEPH and CHIR which may drive the stock lower back to $9 and Chir back to below $20s. Shouldn't have been so greedy and sold CEPH at $15.....Well, we sometime gain BIG and we sometime gain little. Still better than LOSSES. ''At this point, I'm fairly confident Cephalon doesn't have a strong enough case for getting the drug approved. I think it's problematic that after two years of reviewing it, the FDA still needs more time,'' said CIBC Oppenheimer analyst Matt Geller.